Back to Search Start Over

A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification.

Authors :
Bamborough P
Chung CW
Demont EH
Bridges AM
Craggs PD
Dixon DP
Francis P
Furze RC
Grandi P
Jones EJ
Karamshi B
Locke K
Lucas SCC
Michon AM
Mitchell DJ
Pogány P
Prinjha RK
Rau C
Roa AM
Roberts AD
Sheppard RJ
Watson RJ
Source :
Journal of medicinal chemistry [J Med Chem] 2019 Aug 22; Vol. 62 (16), pp. 7506-7525. Date of Electronic Publication: 2019 Aug 09.
Publication Year :
2019

Abstract

The bromodomain of ATAD2 has proved to be one of the least-tractable proteins within this target class. Here, we describe the discovery of a new class of inhibitors by high-throughput screening and show how the difficulties encountered in establishing a screening triage capable of finding progressible hits were overcome by data-driven optimization. Despite the prevalence of nonspecific hits and an exceptionally low progressible hit rate (0.001%), our optimized hit qualification strategy employing orthogonal biophysical methods enabled us to identify a single active series. The compounds have a novel ATAD2 binding mode with noncanonical features including the displacement of all conserved water molecules within the active site and a halogen-bonding interaction. In addition to reporting this new series and preliminary structure-activity relationship, we demonstrate the value of diversity screening to complement the knowledge-based approach used in our previous ATAD2 work. We also exemplify tactics that can increase the chance of success when seeking new chemical starting points for novel and less-tractable targets.

Details

Language :
English
ISSN :
1520-4804
Volume :
62
Issue :
16
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
31398032
Full Text :
https://doi.org/10.1021/acs.jmedchem.9b00673